Suppr超能文献

人类肾上腺皮质肿瘤和嗜铬细胞瘤中无ras基因突变。

Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas.

作者信息

Moul J W, Bishoff J T, Theune S M, Chang E H

机构信息

Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799.

出版信息

J Urol. 1993 Jun;149(6):1389-94. doi: 10.1016/s0022-5347(17)36397-8.

Abstract

A variety of human tumors have been studied for ras mutations to date. However, little is known about the prevalence and significance of ras gene activation in adrenal neoplasms. Recently, a study of 10 primary human pheochromocytomas found no evidence for ras mutations. To our knowledge no survey of ras mutations in adrenocortical neoplasms has been reported. Therefore, we analyzed deoxyribonucleic acid (DNA) from 17 archival tumors (8 adrenocortical carcinomas, 6 pheochromocytomas, 2 adrenal adenomas, 1 aldosteronoma, 2 fresh pheochromocytomas and 1 fresh benign adrenal gland) for activating mutations at the 12, 13 and 61 codons of N-ras, H-ras and K-ras. DNA was extracted from archival tissues using 3 different methods: a simplified boiling method, a proteinase-K-phenol chloroform extraction and a novel heat-stable protease Thermus rt41A technique. The boiling and heat-stable protease methods provided for more consistent polymerase chain reaction amplifications than the more laborious phenol chloroform method. This heat-stable protease Thermus rt41A method had not been reported previously for use in archival DNA extraction. Polymerase chain reaction amplified the ras gene regions of interest, and mutations were screened by mutation-specific oligonucleotide probe hybridization of Southern and slot blots. Polymerase chain reaction-generated mutation-specific positive and negative controls were used in the hybridization protocol. With these controlled conditions no definite mutations were detected at codons 12, 13 or 61 of N, H or K-ras. Ras activation via point mutations at these codons rarely, if ever, occurs in adrenal neoplasms.

摘要

迄今为止,已对多种人类肿瘤进行了ras突变研究。然而,关于ras基因激活在肾上腺肿瘤中的发生率和意义,人们知之甚少。最近,一项对10例原发性人类嗜铬细胞瘤的研究未发现ras突变的证据。据我们所知,尚未有关于肾上腺皮质肿瘤中ras突变的调查报道。因此,我们分析了来自17例存档肿瘤(8例肾上腺皮质癌、6例嗜铬细胞瘤、2例肾上腺腺瘤、1例醛固酮瘤、2例新鲜嗜铬细胞瘤和1例新鲜良性肾上腺组织)的脱氧核糖核酸(DNA),以检测N-ras、H-ras和K-ras基因第12、13和61密码子处的激活突变。使用3种不同方法从存档组织中提取DNA:简化煮沸法、蛋白酶K-酚氯仿提取法和一种新型热稳定蛋白酶嗜热栖热菌rt41A技术。与更繁琐的酚氯仿法相比,煮沸法和热稳定蛋白酶法能提供更一致的聚合酶链反应扩增。此前尚未有关于这种热稳定蛋白酶嗜热栖热菌rt41A法用于存档DNA提取的报道。聚合酶链反应扩增感兴趣的ras基因区域,并通过Southern印迹和狭缝印迹的突变特异性寡核苷酸探针杂交筛选突变。在杂交方案中使用聚合酶链反应产生的突变特异性阳性和阴性对照。在这些受控条件下,未在N、H或K-ras基因的第12、13或61密码子处检测到明确的突变。通过这些密码子处的点突变激活ras在肾上腺肿瘤中极少发生(如果曾经发生过的话)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验